eyeWatch vs. Trabeculectomy RCT (evT) — evT  

Primary Glaucoma Clinical Trial

Official title: Randomized Control Trial of the eyeWatch System as a First-Line Surgical Treatment of Glaucoma vs. MMC-Trabeculectomy

Status Enrolling by invitation

Clinical Trial Summary

The confirm the performance and safety of the eyeWatch System as first-line filtering surgery and compare its outcomes to trabeculectomy

Clinical Trial Description

Open-angle glaucoma is an ophthalmic disease often characterised by high intraocular pressures. Traditionally, glaucoma is treated using medication, however, more advanced or refractory glaucoma requires surgical treatment. In terms of surgery, the current gold-standard is trabeculectomy. Despite good efficacy, the technique carries relatively high rates of complications. The eyeWatch system has recently received CE-marking for the treatment of open-angle glaucoma. During its initial clinical trial, the eyeWatch system demonstrated good safety and efficacy profile. The present randomized control trial will assess its safety and efficacy against the current gold-standard: trabeculectomy. ;

Related Conditions & MeSH terms

• Glaucoma
• Primary Glaucoma

• NCT number: NCT04323930
• Study type: Interventional
• Source: Swiss Vision Network
• Status: Enrolling by invitation
• Phase: N/A
• Start date: June 30, 2021
• Completion date: December 31, 2023